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carcinoma migration and could be manipulated to promote 
anti-tumor immune response. The role of macrophages in this 
system is currently investigated.  
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During the past decades, important progress has been made 
in the treatment of cancer. With early detection and more 
effective treatments, cancer has become a curable disease 
for many patients, while for others it could now be 
considered a chronic disease. As a consequence, the number 
of long-term cancer survivors is rapidly increasing, in 
particular among patients treated for Hodgkin’s lymphoma, 
testicular, prostate, colo-rectal, breast cancer or children’s 
leukemia. 
Most of these patients, however, face immediate (mostly 
transient) and long term (mostly irreversible) physical and 
mental side effects: hair loss, changes in body image, 
fatigue, depression, cognitive dysfunction, as well as 
increased risk of cardiovascular disease, bone loss, infertility 
and secondary malignancies. Cancer survivors are also 
confronted with socio-economical consequences of their 
disease, including too often exclusion from insurances, 
mortgages and loss of jobs. 
Most of the current knowledge regarding the long-term side 
effects of cancer and its treatment is based on registry data 
that is missing important treatment details. Clinical trial 
databases on the other hand include treatment and outcome 
data, but often fail to produce very long-term follow-up of 
outcome and late effects because of the high costs of 
conducting such long-term follow-up. 
The European Organisation for Research and Treatment of 
Cancer (EORTC) Survivorship Task Force aims to use and, if 
needed, to complete the impressive EORTC databases 
accumulated over 50 years of conducting cancer clinical 
trials. The goal is to document and analyse how long-term 
outcomes and side effects are associated with cancer 
treatment. With experience in updates of lymphoma and 
leukemia trials, early breast cancer trials are now being 
assessed as well. These studies provide large patient numbers 
(over 6000 patients for the lymphoma studies and over 
10,000 patients for the early breast cancer cohort). For the 
lymphoma trials, the first results on cardiovascular disease 
and secondary malignancies (incidence and mortality) have 
recently been published. The effects of the different 
treatment components on these endpoints have been 
quantified. Additional information will be gathered through a 
number of questionnaires sent to survivors, asking them 
about the impact of cancer diagnosis and treatment on 
relationships (social situation, parenthood), education, work 
and insurance, fatigue, emotional well-being and quality of 
life. To estimate the relative risks compared to the general 
population, a linkage with data of registries from several 
geographic areas is needed. Establishing such a network will 
enable us to quantify the impact of cancer treatment on late 
side effects in absolute terms. 
The information that the EORTC will gather through this 
series of projects is expected to help and guide future 
patients in trading off treatment efficacy and late side 
effects, seen as important costs in surviving cancer. 
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Radiotherapy (RT) planning and delivery for cancer 
management has substantially evolved over the last three 
decades with lately the introduction of intensity modulated 
RT, image-guided RT and stereotactic ablative RT to name a 
few techniques. The evaluation of these ehigh precision 
delivery techniques in routine care and in clinical trials alike 
requires optimal RT quality (RTQA) assurance programs which 
aim at defining the range of acceptable variations and 
importantly developing mechanisms of action for correction 
and prevention of potential variations[1, 2]. RTQA outside a 
clinical trial is defined by all processes that ensure 
consistency of the dose prescription and the safe delivery of 
that prescription with regard to dose to the target and 
critical structures, minimization of the exposure of the RT 
personnel, particularly so the radiation technologists[3]. In the 
framework of clinical trials assessing the efficacy of RT with 
or without a combined modality, RTQA is also necessary to 
avoid the corruption of the study-endpoint[4], as RT variations 
from study protocol decrease the therapeutic effectiveness 
and/or increase the likelihood of radiation-induced 
toxicities[5]. Prospective trials have shown that RTQA 
variations have a significant impact on the primary study 
end-point and could bias the analysis of the trial results[6]. 
Other specific consideration for RTQA in trials includes, but is 
not limited to, education of the accruing sites in RT-trial 
guidelines, promotion of consistency between centers and 
estimation of inter-patient and inter-institutional variations. 
Additionally, global cooperation is essential in the 
environment of common and rare cancers alike, in order to 
be able to create sufficiently large patient data sets within a 
reasonable recruitment period. This cooperation is not 
without issues and recently the need to have harmonized 
